Equity

Additional Paid-In Capital

Kailera Therapeutics Additional Paid-In Capital increased by 33.4% to $15.98M in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2025
Last reportedQ1 2026May 26, 2026

How to read this metric

An increase indicates equity financing or the issuance of shares for employee compensation, signaling capital raising or dilution.

Detailed definition

This represents the excess amount paid by shareholders for common stock over its par value. It is a primary component of...

Peer comparison

Standard equity account for all publicly traded companies.

Metric ID: equity_additional_paid_in_capital_common_stock

Historical Data

2 periods
 Q4 '25Q1 '26
Value$11.98M$15.98M
QoQ Change—+33.4%
Range$11.98M – $15.98M

Additional Paid-In Capital at Other Companies

CF Industries logo
CF IndustriesCFView metric
Xylem logo
XylemXYLView metric
Willis Towers Watson logo
Willis Towers WatsonWTWView metric
Ameren logo
AmerenAEEView metric
Arch Capital Group logo
Arch Capital GroupACGLView metric
Arch Capital Group logo
Arch Capital GroupACGLView metric

Frequently Asked Questions

What is Kailera Therapeutics 's additional paid-in capital?
Kailera Therapeutics (KLRA) reported additional paid-in capital of $15.98M in Q1 2026.
What does additional paid-in capital mean?
The total amount of money investors paid for shares above the nominal par value.